An early-stage Alexion Pharmaceuticals, specializing in novel therapies for rare pediatric lysosomal storage disorders.

Like a nascent Sarepta Therapeutics, focused on developing innovative treatments for multiple rare, devastating pediatric genetic disorders.

• PLX-200 (gemfibrozil): An oral small molecule, repurposed drug advancing through a Phase 2 basket trial (SOTERIA) for various lysosomal storage disorders (LSDs) like CLN2, CLN3, Krabbe, and Sandhoff diseases.
• PLX-300 (cinnamic acid): A novel, oral small molecule therapy in IND-enabling studies for LSDs, including GM2 gangliosidosis, Krabbe disease, and Niemann-Pick Disease types A and B.
• PLX-100: A preclinical stage orally administrable combination therapy comprising PLX-200 and vitamin A, being developed for LSDs, specifically CLN2.
• PLX-400: A preclinical stage novel gene therapy being explored for the treatment of LSDs, potentially as a monotherapy or in combination with PLX-200.

Polaryx Therapeutics (PLYX) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for rare, pediatric lysosomal storage disorders. As a clinical-stage company, Polaryx Therapeutics does not currently have major customers or categories of customers, as its drug candidates are still in various stages of clinical trials (Phase 2, IND-enabling, and preclinical) and have not yet received regulatory approval for commercial sale. Therefore, the company is not currently generating revenue from product sales.

Alex Yang, J.D., LL.M. - CEO and Chair of the Board

Alex Yang has served as Chair of the Board since June 2021 and Chief Executive Officer since March 2023. He is also the CEO and founder of Mstone Partners. Since 2016, he has served in senior management and chair of board roles for several biopharmaceutical companies. With over 25 years of experience, he has advised and executed fund formation, cross-border transactions, and a diverse range of investment experiences across multiple industry sectors. He currently serves on investment and risk committees for various regional and country-focused private equity funds. Prior roles include managing partner at Kim & Chang and partner at Ernst & Young Hong Kong, where he led regional financial services practice. He also worked at Morgan Stanley Hong Kong Office in Asia Private Equity and In-house Counsel, focusing on buy-outs, grow-capital investments, real estate, special situations, and infrastructure transactions across Asia.

G. Michael Landis, CPA - Chief Financial Officer and Director

G. Michael Landis is an accomplished financial executive with over 25 years of experience in public company expertise, capital market transactions, investor relations, and financial reporting. Immediately prior to joining Polaryx, he was Chief Financial Officer at Epygenix Therapeutics, a late-stage clinical biopharmaceutical company that was acquired in April 2024. He also served as Chief Financial Officer at Avisa Diagnostics Inc., a publicly traded medical device company, where he was responsible for strategic and tactical finance initiatives, investor relations, and capital-raising activities. He also served as Principal Accounting Officer and Treasurer at Lannett Company Inc., a publicly traded pharmaceutical company.

Dr. Lisa L. Bollinger, M.D. - Chief Medical Officer

Dr. Lisa Bollinger is a board-certified pediatrician with over 30 years of experience in drug development, possessing deep expertise in regulatory affairs and clinical safety. Before joining Polaryx, she founded Bollinger Regulatory Consulting (BRC), where she provided regulatory and clinical expertise to venture capital firms. Her previous roles include Vice President of Regulatory Affairs at Merck Sharp & Dohme and senior positions at Amgen.

Eddy Zhu, Ph.D., PMP - Chief CMC Officer

Eddy Zhu is a highly accomplished scientific professional, specializing in chemistry, manufacturing, and controls (CMC) management with over 20 years of experience in commercial manufacturing, pharmaceutical development, and regulatory approvals. He has a proven track record of success as a leader in technical R&D excellence in both multinational corporation (MNC) and small startup environments, resulting in numerous peer-reviewed publications and several formulation patents. Prior to Polaryx, he served as Product Development Lead at Sanofi, playing a critical role in pharmaceutical and non-pharmaceutical formulation and development across oral solids, liquids, and injectables.

Dr. Shrijay Vijayan, Ph.D. - Chief Scientific and Business Development Officer

Dr. Shrijay Vijayan is a highly experienced biomedical technology commercialization executive with an extensive industry network and more than 20 years of technical expertise.

The key risks for Polaryx Therapeutics (PLYX) are primarily centered around its status as a clinical-stage biotechnology company developing treatments for rare diseases.

1. Clinical Trial Success and Regulatory Approval: As a clinical-stage company, the paramount risk for Polaryx Therapeutics is the successful outcome of its ongoing and planned clinical trials, particularly the Phase 2 SOTERIA basket trial for its most advanced candidate, PLX-200. The company's future development pathway for its multiple indications is explicitly dependent on data readouts from SOTERIA. Even with positive trial results, obtaining regulatory approval from the U.S. Food and Drug Administration (FDA) is not guaranteed, despite receiving designations like Orphan Drug and Fast Track, which the company states "does not guarantee a faster development process, regulatory review, or approval". The background also notes previous delays in initiating trials due to the COVID-19 pandemic and a subsequent shift in strategy, highlighting the potential for further delays.
2. Competition from Existing Therapies and Standards of Care: For some of the rare lysosomal storage disorders (LSDs) that Polaryx Therapeutics targets, existing treatments or established standards of care are already available. For instance, CLN2, one of the NCL subtypes, has an established enzyme replacement therapy. Krabbe disease has hematopoietic stem cell transplantation (HSCT) as the current standard of care. Additionally, an enzyme replacement therapy has been approved for Niemann-Pick Disease (NPD) types A and B, although it does not treat neurological symptoms. Polaryx's drug candidates will need to demonstrate clear advantages in efficacy, safety, or patient convenience to compete effectively with these established options and gain market adoption.
3. Dependence on a Limited Pipeline of Advanced Drug Candidates: While Polaryx Therapeutics has a pipeline of drug candidates, including PLX-200, PLX-300, PLX-100, and PLX-400, the company's immediate strategy and resource allocation are heavily focused on the PLX-200 program, particularly the SOTERIA trial. The company has explicitly stated that it does not expect to commence previously authorized pivotal trials for CLN2 and CLN3 in the near term, opting instead to focus resources on SOTERIA. A significant setback or failure in the development of PLX-200 could therefore have a disproportionately large impact on the company's overall prospects and valuation.

For Polaryx Therapeutics (PLYX), the addressable markets for their main products, which target various Lysosomal Storage Disorders (LSDs), are as follows:

• Neuronal Ceroid Lipofuscinoses (NCLs): Approximately 7,700 patients in the United States, Europe, and select regions of the rest of the world (ROW).
• Krabbe Disease: Approximately 6,700 patients in the United States, Europe, and select regions of the ROW.
• Sandhoff Disease (a type of GM2 gangliosidosis): Approximately 1,200 patients in the United States, Europe, and select regions of the ROW.

Here are 3-5 expected drivers of future revenue growth for Polaryx Therapeutics (PLYX) over the next 2-3 years:

1. Accelerated Approval and Commercialization of PLX-200 for CLN2 and CLN3: Polaryx Therapeutics believes there is an opportunity to seek accelerated approval for its most advanced drug candidate, PLX-200, for the treatment of Classic Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2) and Juvenile Neuronal Ceroid Lipofuscinosis (CLN3). If successful, this could lead to the company's first commercial product and a significant revenue stream within the specified timeframe.
2. Successful Advancement of PLX-200 through the SOTERIA Basket Trial Leading to Registrable Studies for Multiple Lysosomal Storage Disorders (LSDs): The SOTERIA trial, a Phase 2 proof-of-concept basket trial for PLX-200, is expected to initiate in the first half of 2026 and targets several LSDs, including CLN2, CLN3, Krabbe disease, and Sandhoff disease. Positive data readouts from this multi-indication study are anticipated to provide a clear pathway for each of the four indications towards potentially registrable trials, thereby expanding the potential market reach and future revenue streams for PLX-200 beyond initial accelerated approvals.
3. Potential for Strategic Partnerships or Licensing Agreements Driven by Positive Clinical Data for PLX-200: As a clinical-stage biotechnology company, positive clinical data, especially from the SOTERIA trial, could make PLX-200 and Polaryx Therapeutics an attractive candidate for strategic collaborations or licensing agreements. Such partnerships could provide upfront payments, milestone achievements, and royalties, contributing to revenue growth as the drug progresses towards commercialization across various LSD indications.

Share Issuance

• Polaryx Therapeutics significantly increased its Additional Paid In Capital, a key indicator of funds raised through equity offerings. This figure grew from $61.6 million in December 2023 to $95.3 million in December 2024, representing an issuance of $33.7 million in shares during that period.
• The company continued to issue shares, with Additional Paid In Capital increasing by another $8.1 million from December 2024 to $103.4 million by the last reported quarter of 2025.
• Overall, Polaryx Therapeutics issued approximately $41.8 million in shares between December 2023 and the end of 2025.

Inbound Investments

• Significant inbound investment has occurred through equity financing, evidenced by the increase in Additional Paid In Capital by $41.8 million from December 2023 to the end of 2025.
• A Schedule 13D filing in February 2026 indicated that major holders collectively reported 48% ownership in Polaryx Therapeutics, signifying substantial institutional investment in the company.

Capital Expenditures

• As a clinical-stage biotechnology company primarily focused on research and development, Polaryx Therapeutics' capital expenditures are likely directed towards laboratory equipment and facilities to support its drug pipeline development.